These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 39284338

  • 1. Cognitive performance, neuropsychiatric symptoms, and cerebrospinal fluid viral control following programmatic switch from efavirenz-based to dolutegravir-based antiretroviral therapy in South Africa (CONNECT): a prospective cohort study.
    Nightingale S, Dreyer AJ, Thomas KGF, van Zyl G, Decloedt E, Naude PJW, Orrell C, Sinxadi P, Winston A, Khoo S, Joska JA.
    Lancet HIV; 2024 Oct; 11(10):e680-e689. PubMed ID: 39284338
    [Abstract] [Full Text] [Related]

  • 2. Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial.
    Kintu K, Malaba TR, Nakibuka J, Papamichael C, Colbers A, Byrne K, Seden K, Hodel EM, Chen T, Twimukye A, Byamugisha J, Reynolds H, Watson V, Burger D, Wang D, Waitt C, Taegtmeyer M, Orrell C, Lamorde M, Myer L, Khoo S, DolPHIN-2 Study Group.
    Lancet HIV; 2020 May; 7(5):e332-e339. PubMed ID: 32386721
    [Abstract] [Full Text] [Related]

  • 3. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.
    Venter WDF, Sokhela S, Simmons B, Moorhouse M, Fairlie L, Mashabane N, Serenata C, Akpomiemie G, Masenya M, Qavi A, Chandiwana N, McCann K, Norris S, Chersich M, Maartens G, Lalla-Edward S, Vos A, Clayden P, Abrams E, Arulappan N, Hill A.
    Lancet HIV; 2020 Oct; 7(10):e666-e676. PubMed ID: 33010240
    [Abstract] [Full Text] [Related]

  • 4. Risks and Benefits of Dolutegravir- and Efavirenz-Based Strategies for South African Women With HIV of Child-Bearing Potential: A Modeling Study.
    Dugdale CM, Ciaranello AL, Bekker LG, Stern ME, Myer L, Wood R, Sax PE, Abrams EJ, Freedberg KA, Walensky RP.
    Ann Intern Med; 2019 May 07; 170(9):614-625. PubMed ID: 30934067
    [Abstract] [Full Text] [Related]

  • 5. 72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study.
    Malaba TR, Nakatudde I, Kintu K, Colbers A, Chen T, Reynolds H, Read L, Read J, Stemmet LA, Mrubata M, Byrne K, Seden K, Twimukye A, Theunissen H, Hodel EM, Chiong J, Hu NC, Burger D, Wang D, Byamugisha J, Alhassan Y, Bokako S, Waitt C, Taegtmeyer M, Orrell C, Lamorde M, Myer L, Khoo S, DolPHIN-2 Study Group.
    Lancet HIV; 2022 Aug 07; 9(8):e534-e543. PubMed ID: 35905752
    [Abstract] [Full Text] [Related]

  • 6. Assessment of weight gain in adult patients living with HIV receiving first-line dolutegravir-based or efavirenz-based ART regimens in routine care clinics in Tshwane district, South Africa: An observational study.
    Sawry S, Ayalew K, Maimela G, Briggs-Hagen M, van Wyk-Heath M, Mthethwa S, Shai S, Mngomezulu NN, Tlhowe L, Achere-Darko J, Bedford J, Martin CE, Fairlie L, Imrie J.
    HIV Med; 2024 Jul 07; 25(7):826-839. PubMed ID: 38520085
    [Abstract] [Full Text] [Related]

  • 7. Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines.
    Phillips AN, Bansi-Matharu L, Venter F, Havlir D, Pozniak A, Kuritzkes DR, Wensing A, Lundgren JD, Pillay D, Mellors J, Cambiano V, Jahn A, Apollo T, Mugurungi O, Ripin D, Da Silva J, Raizes E, Ford N, Siberry GK, Gupta RK, Barnabas R, Revill P, Cohn J, Calmy A, Bertagnolio S.
    Lancet HIV; 2020 Mar 07; 7(3):e193-e200. PubMed ID: 32035041
    [Abstract] [Full Text] [Related]

  • 8. Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study.
    Zash R, Jacobson DL, Diseko M, Mayondi G, Mmalane M, Essex M, Gaolethe T, Petlo C, Lockman S, Holmes LB, Makhema J, Shapiro RL.
    Lancet Glob Health; 2018 Jul 07; 6(7):e804-e810. PubMed ID: 29880310
    [Abstract] [Full Text] [Related]

  • 9. A randomized comparison of health-related quality of life outcomes of dolutegravir versus efavirenz-based antiretroviral treatment initiated in the third trimester of pregnancy.
    Ochanda PN, Lamorde M, Kintu K, Wang D, Chen T, Malaba T, Myer L, Waitt C, Reynolds H, Khoo S.
    AIDS Res Ther; 2022 Jun 07; 19(1):24. PubMed ID: 35672853
    [Abstract] [Full Text] [Related]

  • 10. Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis.
    Kanters S, Vitoria M, Doherty M, Socias ME, Ford N, Forrest JI, Popoff E, Bansback N, Nsanzimana S, Thorlund K, Mills EJ.
    Lancet HIV; 2016 Nov 07; 3(11):e510-e520. PubMed ID: 27658869
    [Abstract] [Full Text] [Related]

  • 11. Tryptophan metabolism and its relationship with central nervous system toxicity in people living with HIV switching from efavirenz to dolutegravir.
    Keegan MR, Winston A, Higgs C, Fuchs D, Boasso A, Nelson M.
    J Neurovirol; 2019 Feb 07; 25(1):85-90. PubMed ID: 30478800
    [Abstract] [Full Text] [Related]

  • 12. Comparison of dolutegravir and efavirenz on depression, anxiety and sleep disorders in pregnant and postpartum women living with HIV.
    van der Wekken-Pas L, Nassiwa S, Malaba T, Lamorde M, Myer L, Waitt C, Reynolds H, Khoo S, He N, van Leeuwen L, Burger D, Wang D, Colbers A.
    AIDS; 2024 Jun 01; 38(7):975-981. PubMed ID: 38277390
    [Abstract] [Full Text] [Related]

  • 13. Implications of Efavirenz Pharmacogenetics When Switching From Efavirenz- to Dolutegravir-containing Antiretroviral Regimens.
    Haas DW, Acosta EP.
    Clin Infect Dis; 2021 May 18; 72(10):1820-1822. PubMed ID: 32667979
    [Abstract] [Full Text] [Related]

  • 14. Real-world use and outcomes of dolutegravir-containing antiretroviral therapy in HIV and tuberculosis co-infection: a site survey and cohort study in sub-Saharan Africa.
    Romo ML, Brazier E, Mahambou-Nsondé D, De Waal R, Sekaggya-Wiltshire C, Chimbetete C, Muyindike WR, Murenzi G, Kunzekwenyika C, Tiendrebeogo T, Muhairwe JA, Lelo P, Dzudie A, Twizere C, Rafael I, Ezechi OC, Diero L, Yotebieng M, Fenner L, Wools-Kaloustian KK, Shah NS, Nash D, International epidemiology Databases to Evaluate AIDS (IeDEA).
    J Int AIDS Soc; 2022 Jul 18; 25(7):e25961. PubMed ID: 35848120
    [Abstract] [Full Text] [Related]

  • 15. Virologic outcomes on dolutegravir-, atazanavir-, or efavirenz-based ART in urban Zimbabwe: A longitudinal study.
    Shamu T, Egger M, Mudzviti T, Chimbetete C, Manasa J, Anderegg N.
    PLoS One; 2024 Jul 18; 19(2):e0293162. PubMed ID: 38394297
    [Abstract] [Full Text] [Related]

  • 16. Comparative Effects of Efavirenz and Dolutegravir on Metabolomic and Inflammatory Profiles, and Platelet Activation of People Living with HIV: A Pilot Study.
    Roux CG, Mason S, du Toit LDV, Nel JG, Rossouw TM, Steel HC.
    Viruses; 2024 Sep 14; 16(9):. PubMed ID: 39339938
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Changes in functional connectivity in people with HIV switching antiretroviral therapy.
    Toniolo S, Cercignani M, Mora-Peris B, Underwood J, Alagaratnam J, Bozzali M, Boffito M, Nelson M, Winston A, Vera JH.
    J Neurovirol; 2020 Oct 14; 26(5):754-763. PubMed ID: 32500477
    [Abstract] [Full Text] [Related]

  • 19. Implementation and outcomes of dolutegravir-based first-line antiretroviral therapy for people with HIV in South Africa: a retrospective cohort study.
    Dorward J, Sookrajh Y, Khubone T, van der Molen J, Govender R, Phakathi S, Lewis L, Bottomley C, Maraj M, Lessells RJ, Naidoo K, Butler CC, Van Heerden R, Garrett N.
    Lancet HIV; 2023 May 14; 10(5):e284-e294. PubMed ID: 37001536
    [Abstract] [Full Text] [Related]

  • 20. Viremia and HIV Drug Resistance Among People Receiving Dolutegravir Versus Efavirenz-Based First-Line Antiretroviral Therapy.
    Dorward J, Sookrajh Y, Lessells R, Bulo E, Bodley N, Singh L, Moodley P, Samsunder N, Drain PK, Hayward G, Butler CC, Garrett N.
    J Acquir Immune Defic Syndr; 2024 Apr 15; 95(5):e8-e11. PubMed ID: 38489494
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.